Clinical trials: Posterior Blepharitis
- Condition Posterior Blepharitis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Meibomian Glands, Dry Eye Syndromes
Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease
This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).
- Trial name
- NCT03226769
- Testing
- TrueTear™, Thermalon Dry Eye Compress
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Allergan
Dry Eye, Meibomian Gland Dysfunction
TearCare System to Treat Dry Eye Disease
In this study, the TearCare System will be compared with the LipiFlow Thermal Pulsation System in patients with dry eye disease.
- Trial name
- OLYMPIA (NCT03857919)
- Testing
- TearCare, LipiFlow
- Where
- 10 sites in United States
- Volunteers
- 235 people
- Sponsor
- Sight Sciences, Inc.
Dry Eye Disease (DED)
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland…
- Trial name
- NCT04139798
- Testing
- NOV03
- Where
- 29 sites in United States
- Volunteers
- 599 people
- Sponsor
- Bausch & Lomb Incorporated
Meibomian Gland Dysfunction
Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction
STUDY DESIGN Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study. Duration: 3 months of TID treatment.
- Trial name
- NCT04884243
- Testing
- CBT-006
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
- Trial name
- NCT03972501
- Testing
- AZR-MD-001 Vehicle, AZR-MD-001 Active Dose
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Azura Ophthalmics
Blepharitis
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
- Trial name
- Maui (NCT02218489)
- Testing
- KPI-121, Vehicle
- Where
- 8 sites in United States
- Volunteers
- 206 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Syndrome
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03396913
- Testing
- IPL, MGX
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Lumenis Be Ltd.
Meibomian Gland Dysfunction
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the iLux® 2020 System or the LipiFlow® Thermal…
- Trial name
- NCT03055832
- Testing
- iLux 2020 System, LipiFlow Pulsation System
- Where
- 7 sites in United States
- Volunteers
- 142 people
- Sponsor
- Tear Film Innovations, Inc.
Dry Eye, Meibomian Gland Dysfunction
Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)
To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.
- Trial name
- NCT04795752
- Testing
- TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
- Where
- 14 sites in United States
- Volunteers
- 345 people
- Sponsor
- Sight Sciences, Inc.
Meibomian Gland Dysfunction
A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction
This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.
- Trial name
- NCT01633788
- Testing
- AGN-195263 0.1%, AGN-195263 0.03%, AGN-195263 0.01%
- Where
- 33 sites in United States
- Volunteers
- 232 people
- Sponsor
- Allergan
Meibomian Gland Dysfunction
Safety, Efficacy and Pharmacokinetics of CBT-008 in Patients With Meibomian Gland Dysfunction
Study Design Structure: Multicenter, randomized, double-masked, vehicle-controlled, parallel group study Duration: 1 month of TID treatment Treatment Groups, Dosing, and Treatment Regimen Study Treatment: CBT-008 topical…
- Trial name
- NCT05261386
- Testing
- CBT-008
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Cloudbreak Therapeutics, LLC
Evaporative Dry Eye
iLux Treatment for Meibomian Gland Dysfunction (MGD)
The purpose of this study is to assess changes in meibomian gland function and evaporative dry eye symptoms after treatment with the iLux medical device.
- Trial name
- NCT03055650
- Testing
- iLux 2020 System
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tear Film Innovations, Inc.
Meibomian Gland Dysfunction, Evaporative Dry Eye
Tear Film Innovations iLux Safety Study
The objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the iLux device using the protocol treatment profile.
- Trial name
- NCT03055897
- Testing
- iLux 2020 System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Tear Film Innovations, Inc.
Dry Eye Disease
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with…
- Trial name
- NCT04567329
- Testing
- NOV03, Saline Solution
- Where
- 35 sites in United States
- Volunteers
- 620 people
- Sponsor
- Bausch & Lomb Incorporated
Meibomian Gland Dysfunction, Dry Eye
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
The pilot study objective is to evaluate the potential benefits of LipiFlow® System treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye by assessing for improvement in meibomian gland…
- Trial name
- NCT02102464
- Testing
- LipiFlow treatment
- Where
- 6 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- TearScience, Inc.
Meibomian Gland Dysfunction, Dry Eye
A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)
AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
- Trial name
- NCT03652051
- Testing
- AZR-MD-001 Low Dose, AZR-MD-001 Mid Dose, AZR-MD-001 High Dose
- Where
- 30 sites in Australia, Canada and 1 more
- Volunteers
- 321 people
- Sponsor
- Azura Ophthalmics
Improvement of Dry Eye Disease
Radio Frequency (Forma Eye) Treatment for Dry Eye Disease Due to Meibomian Gland Dysfunction
The aim of the study is to evaluate the safety and efficacy of radiofrequency treatment for dry eye disease due to meibomian gland dysfunction
- Trial name
- NCT04120584
- Testing
- Forma Eye Applicator
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- InMode MD Ltd.
Meibomian Gland Dysfunction
Evaluation of the LipiFlow System With a New Activator
Minimum 50 eyes and up to 100 eyes will be treated in this prospective, open-label clinical study. The investigator or designee will perform LipiFlow treatment with the Activators LFD-2100 on both eyes of a subject.
- Trial name
- NCT04500821
- Testing
- Activator LFD-2100
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Bilateral Blepharitis (Disorder)
To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis
The purpose of this study is to evaluate the efficacy of, and patient satisfaction with Blephapad Combo in the treatment of posterior blepharitis.
- Trial name
- NCT03301844
- Testing
- Blephapad Combo, Standard treatment
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- NTC srl
Cataracts, Meibomian Gland Dysfunction (MGD)
A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice
This is a post-market, prospective, randomized, multi-center, bilateral, open-label, cross-over, comparative clinical study. Study group will undergo preoperative LipiFlow treatment and Control group will not receive preoperative…
- Trial name
- NCT03708367
- Testing
- LipiFlow Thermal Pulsation System
- Where
- 5 sites in United States
- Volunteers
- 117 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.